brand logo

Am Fam Physician. 2022;105(5):542-543

Author disclosure: No relevant financial relationships.

MyProstateScore (MPS; also referred to as Michigan Prostate Score) combines serum prostate-specific antigen (PSA) levels with the urinary biomarkers prostate cancer antigen 3 (PCA3) and TMPRSS2: ERG gene fusion to estimate the risk of prostate cancer. MPS is marketed as a tool for determining the likelihood of detecting clinically significant prostate cancer on biopsy.13 It may help patients and physicians decide whether to proceed with a prostate biopsy.

MyProstateScoreEstimate risk of clinically significant prostate cancer (grade group 2 or higher) to determine need for prostate biopsyAdults who are referred for prostate biopsy$760
Already a member/subscriber?  Log In


From $165
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available

Issue Access

  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

This series is coordinated by Natasha Pyzocha, DO, contributing editor.

A collection of Diagnostic Tests published in AFP is available at

Continue Reading

More in AFP

More in Pubmed

Copyright © 2022 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.